AC Immune SA (ACIU)
2.39
-0.06
(-2.45%)
USD |
NASDAQ |
Oct 16, 16:00
2.385
0.00 (0.00%)
After-Hours: 20:00
AC Immune Research and Development Expense (Annual) : 67.96M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 67.96M |
| December 31, 2024 | 71.05M |
| December 31, 2023 | 60.76M |
| December 31, 2022 | 63.17M |
| December 31, 2021 | 68.12M |
| December 31, 2020 | 63.38M |
| Date | Value |
|---|---|
| December 31, 2019 | 50.75M |
| December 31, 2018 | 45.24M |
| December 31, 2017 | 32.60M |
| December 31, 2016 | 25.88M |
| December 31, 2015 | 17.41M |
| December 31, 2014 | 17.28M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Precigen, Inc. | 40.06M |
| Basilea Pharmaceutica AG | 127.51M |
| Santhera Pharmaceuticals Holding AG | 26.75M |
| Aldeyra Therapeutics, Inc. | 25.66M |
| BeOne Medicines Ltd. | 2.079B |